This trial will help researchers learn more about how well inebilizumab works to prevent flare-ups in IgG4-related disease, and if it is safe to use.
- IgG4-Related Disease
1 Primary · 11 Secondary · Reporting Duration: Day 1 to Day 2273
Side Effects for
2 Treatment Groups
1 of 2
1 of 2
160 Total Participants · 2 Treatment Groups
Primary Treatment: Inebilizumab · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any patients who have yet to enroll in this research study?
"The latest information from clinicaltrials.gov reports that this study is still recruiting patients. The trial was first posted on October 26th, 2020 and updated most recently on October 19th, 2022." - Anonymous Online Contributor
To the best of your knowledge, has there been extensive research on Inebilizumab in the past?
"At this time, there are 3 clinical trials underway that focus on Inebilizumab. Out of those 3, 2 are currently in Phase 3. Most studies related to Inebilizumab's efficacy are located in Lille Cedex, Utah; however,217 different locations worldwide are running trials for this medication." - Anonymous Online Contributor
What is the current standing of Inebilizumab in regards to federal approval?
"Our analysts at Power have Inebilizumab's safety rated as a 3. This is based on the fact that this medication is in Phase 3 trials, where there is both efficacy and safety data from multiple rounds of testing." - Anonymous Online Contributor
How many patients are enrolled in this clinical trial?
"In order to carry out the planned research, a total of 160 eligible patients are needed. The trial will be conducted by Viela Bio (now owned by Horizon Therapeutics) at various sites; two examples being Viela Bio Investigative Site 1 in Palo Alto, California and Viela Bio Investigative Site 2 situated in Baltimore, Maryland." - Anonymous Online Contributor
Have there been previous studies like this one?
"Research for inebilizumab began in 2020 with the earliest study being sponsored by Viela Bio. After the first Phase 3 trial, which included 270 people, the drug was approved. Now, there are three active studies taking place in 28 countries and 48 cities." - Anonymous Online Contributor